Enliven Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced the commencement of an underwritten public offering valued at $200 million. The offering includes shares of its common stock and pre-funded warrants for those investors opting for them instead of the common stock. Additionally, Enliven may grant underwriters a 30-day option to purchase up to an extra $30 million in common stock. The offering is contingent on market conditions, with no assurance of completion or specific terms. Jefferies, Goldman Sachs & Co. LLC, TD Cowen, and Mizuho are serving as joint book-running managers, and LifeSci Capital is acting as lead manager for the offering.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。